drugset / Trial / NCT03273088

Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects

NCT03273088

Phase 1 Completed 34 enrolled AryoGen Pharmed Co.
RandomizedCrossoverQuadruple-blindBasic science

Summary

This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate Altebrel relative to etanercept reference product (Enbrel®) and evaluate safety and tolerability of Altebrel, in a crossover fashion in healthy male volunteers after administration of a single dose (25 mg) of etanercept. The primary objective of this study is to demonstrate that the PK of Altebrel is similar to its originator, Enbrel®, as assessed by the area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax. The secondary objectives of the study are: To further compare the PK of Altebrel and Enbrel®. To assess the safety of Altebrel.

Timeline

Start
2016-12-04
Primary completion
2017-03-15
Completion
2017-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous

Indications

No indication recorded.